← Oncology Approval Tracker

FDA DECISION ·

Breyanzi

lisocabtagene maraleucel · Juno Therapeutics (Bristol Myers Squibb)

Accelerated approvalNew or expanded indicationFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Feb 20, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with relapsed or refractory follicular lymphoma after two or more prior systemic treatment lines.

LAMPGEN ANALYSIS

Why it matters

The accelerated approval extended CAR T therapy to a later-line follicular lymphoma population.

What research teams should watch

Collect prior systemic regimen and relapse dates and plan for long-term safety and response follow-up after infusion.

PRIMARY RECORDS

Sources